Amir Hadi1, Hamed Mohammadi1, Maryam Miraghajani2,3, Ehsan Ghaedi4. 1. a Department of Clinical Nutrition, School of Nutrition and Food Science, Student Research Committee, Isfahan University of Medical Sciences , Isfahan , Iran. 2. b National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences , Tehran , Iran. 3. c The Early Life Research Unit, Division of Child Health, Obstetrics and Gynaecology, University of Nottingham , Nottingham , UK. 4. d Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences , Tehran , Iran.
Abstract
Objective: We systematically reviewed available randomized clinical trials (RCTs) to elucidate the overall effects of synbiotic supplementation in patients with nonalcoholic fatty liver disease (NAFLD). Methods: PubMed, Scopus, ISI Web of science and Google Scholar were searched up to December, 2017. All RCTs using synbiotic supplements to treat NAFLD included in this systematic review and meta-analysis. Mean Difference (MD) was pooled using a random-effects model. Results: Eleven eligible databases from seven RCTs were identified for the present meta-analysis. Our results showed that synbiotic supplementation can decrease body weight, fasting blood sugar, insulin, low density lipoprotein cholesterol, total cholesterol, triglyceride, high-sensitivity C-reactive protein, tumor necrosis factor alpha, alanine transaminase and aspartate transaminase levels among patients with NAFLD. In contrast, synbiotic did not have favorable effects on body mass index (BMI), waist circumference, homeostasis model assessment for insulin resistance (HOMA-IR), and high density lipoprotein cholesterol (HDL) levels compared with the placebo group. Conclusion: The current study revealed that synbiotic supplementation has favorable effect on inflammatory factors, liver enzymes and some anthropometric indices, lipid profiles and glucose homeostasis parameters in patients with NAFLD.
Objective: We systematically reviewed available randomized clinical trials (RCTs) to elucidate the overall effects of synbiotic supplementation in patients with nonalcoholic fatty liver disease (NAFLD). Methods: PubMed, Scopus, ISI Web of science and Google Scholar were searched up to December, 2017. All RCTs using synbiotic supplements to treat NAFLD included in this systematic review and meta-analysis. Mean Difference (MD) was pooled using a random-effects model. Results: Eleven eligible databases from seven RCTs were identified for the present meta-analysis. Our results showed that synbiotic supplementation can decrease body weight, fasting blood sugar, insulin, low density lipoprotein cholesterol, total cholesterol, triglyceride, high-sensitivity C-reactive protein, tumor necrosis factor alpha, alanine transaminase and aspartate transaminase levels among patients with NAFLD. In contrast, synbiotic did not have favorable effects on body mass index (BMI), waist circumference, homeostasis model assessment for insulin resistance (HOMA-IR), and high density lipoprotein cholesterol (HDL) levels compared with the placebo group. Conclusion: The current study revealed that synbiotic supplementation has favorable effect on inflammatory factors, liver enzymes and some anthropometric indices, lipid profiles and glucose homeostasis parameters in patients with NAFLD.
Authors: Elisabeth Erhardtsen; Daniel G K Rasmussen; Peder Frederiksen; Diana Julie Leeming; Diane Shevell; Lise Lotte Gluud; Morten Asser Karsdal; Guruprasad P Aithal; Jörn M Schattenberg Journal: JHEP Rep Date: 2021-07-10
Authors: Eleonora Scorletti; Paul R Afolabi; Elizabeth A Miles; Debbie E Smith; Amal Almehmadi; Albandri Alshathry; Caroline E Childs; Stefania Del Fabbro; Josh Bilson; Helen E Moyses; Geraldine F Clough; Jaswinder K Sethi; Janisha Patel; Mark Wright; David J Breen; Charles Peebles; Angela Darekar; Richard Aspinall; Andrew J Fowell; Joanna K Dowman; Valerio Nobili; Giovanni Targher; Nathalie M Delzenne; Laure B Bindels; Philip C Calder; Christopher D Byrne Journal: Gastroenterology Date: 2020-01-25 Impact factor: 33.883
Authors: Kelly S Swanson; Glenn R Gibson; Robert Hutkins; Raylene A Reimer; Gregor Reid; Kristin Verbeke; Karen P Scott; Hannah D Holscher; Meghan B Azad; Nathalie M Delzenne; Mary Ellen Sanders Journal: Nat Rev Gastroenterol Hepatol Date: 2020-08-21 Impact factor: 46.802
Authors: Yasaman Vali; Jenny Lee; Jérôme Boursier; René Spijker; Joanne Verheij; M Julia Brosnan; Quentin M Anstee; Patrick M Bossuyt; Mohammad Hadi Zafarmand Journal: J Clin Med Date: 2021-05-29 Impact factor: 4.241